Orexigen rises as Contrave launches in tough obesity market
This article was originally published in Scrip
Executive Summary
It may be a good omen for the launch of Contrave (naltrexone/bupropion), the newly approved prescription weight loss drug developed by Orexigen Therapeutics and marketed by Takeda Pharmaceutical: a specialty pharmacy service set up to fill prescriptions for Contrave ran into technical difficulties during its first few weeks due to higher-than-expected demand.